| References |
1. Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6. PubMed PMID: 9732378. 2. Herr RJ, Vogt PF, Meckler H, Trova MP, Schow SR, Petter RC. Preparation of 8-substituted xanthine CVT-124 precursor by late stage pyrimidine ring closure. J Org Chem. 2002 Jan 11;67(1):188-93. PubMed PMID: 11777458. 3. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002 Mar 19;105(11):1348-53. Erratum in: Circulation 2002 Sep 24;106(13):1743. PubMed PMID: 11901047. 4. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol. 2000 Jan;35(1):56-9. PubMed PMID: 10636259. |
